Source comparison
Peptides for Broken Bone Recovery: Clinical vs Preclinical Evidence Comparison
BPC-157 VEGF upregulation, angiogenesis, collagen synthesis Preclinical (animal models) 200–500 mcg/day subcutaneous 31% reduction in fracture healing time (tibial fractures, rat model) Most robust preclinical data for bone-tendon healing; no Phase III human t
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, angiogenesis, collagen synthesis
- Preclinical (animal models)
- 200–500 mcg/day subcutaneous
- 31% reduction in fracture healing time (tibial fractures, rat model)
- Most robust preclinical data for bone-tendon healing; no Phase III human trials yet
- TB-500
- Cell migration, anti-inflammatory, actin polymerization
- 2–5 mg twice weekly
- 42% reduction in inflammation markers; 36% reduction in edema
- Strong mechanistic rationale; limited direct bone healing studies in humans
- CJC-1295/Ipamorelin
- GH/IGF-1 elevation, osteoblast stimulation
- Clinical (human studies, non-fracture populations)
- 100–200 mcg each before bed
- 28% increase in bone formation markers over 8 weeks
- Indirect mechanism; evidence from bone density studies in aging populations
- MK-677 (Ibutamoren)
- GH secretagogue, IGF-1 elevation
- Clinical (human trials)
- 25 mg daily
- 7% increase in bone mineral density over 12 months (elderly cohort)
- Oral bioavailability; long-term data available; slower onset than injectable peptides